Asio Capital LLC Takes $2.86 Million Position in Pfizer Inc. $PFE

Asio Capital LLC purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 114,830 shares of the biopharmaceutical company’s stock, valued at approximately $2,859,000.

A number of other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC lifted its holdings in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC lifted its holdings in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares in the last quarter. United Bank lifted its holdings in shares of Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after purchasing an additional 6,415 shares in the last quarter. Cary Street Partners Investment Advisory LLC lifted its holdings in shares of Pfizer by 79.1% during the second quarter. Cary Street Partners Investment Advisory LLC now owns 4,941 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 2,182 shares in the last quarter. Finally, Transce3nd LLC lifted its holdings in shares of Pfizer by 59.4% during the second quarter. Transce3nd LLC now owns 1,879 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 700 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer filed a new Phase 1 study (PF-07328948), signaling continued pipeline investment and R&D momentum that supports longer-term growth prospects. Pfizer’s New Phase 1 PF-07328948 Study Signals Ongoing Pipeline Investment
• Positive Sentiment: Optimistic retail/analyst takes: at least one bullish piece argues PFE looks undervalued and could be a strong buy over a multi-year horizon, which can support investor appetite for the stock on dips. Prediction: In 5 Years, You’ll Wish You Bought Pfizer Stock Today
• Neutral Sentiment: Market correlation: some coverage notes today’s action is tied to broader S&P 500 moves rather than company-specific news, which can amplify price swings independent of fundamentals. Pfizer Inc. Market Action Tied To S&P 500 Index Movement
• Neutral Sentiment: Feature pieces weigh reasons to watch PFE while advising caution — helpful context for investors assessing valuation versus near-term risks. 2 Reasons to Watch PFE and 1 to Stay Cautious
• Neutral Sentiment: Sector competitive landscape: coverage of the expanding “diabesity” (GLP‑1) market highlights big opportunities for peers like Lilly and Novo Nordisk — an indirect signal that competition and missed participation in the category could pressure Pfizer’s long‑term growth narrative. The $190 Billion ‘Diabesity’ Market Is Set to Explode. Lilly and Novo Face These Stock Catalysts.
• Negative Sentiment: Clinical setback: Pfizer and its COVID‑19 vaccine partner paused an updated‑shot trial, which prompted immediate selling pressure and raises short‑term uncertainty about their COVID franchise strategy. Why Is Pfizer Stock Dropping Tuesday?
• Negative Sentiment: Policy risk: reports that a Washington proposal could impose steep tariffs (or a 100% framework) on drugmakers without pricing agreements added regulatory and political risk that can pressure valuations in the near term. Why Is Pfizer Stock Dropping Tuesday?
• Negative Sentiment: Market reaction note: headline summaries show the stock has moved lower amid these combined factors, which explains today’s downward price action versus recent highs. Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on PFE shares. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a report on Monday, March 2nd. Bank of America decreased their price objective on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, December 15th. BMO Capital Markets reissued an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a report on Monday, March 9th. UBS Group assumed coverage on shares of Pfizer in a report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price objective for the company. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $28.19.

Pfizer Stock Performance

Shares of PFE opened at $27.10 on Wednesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. Pfizer Inc. has a one year low of $20.92 and a one year high of $28.75. The firm has a market capitalization of $154.07 billion, a P/E ratio of 19.92 and a beta of 0.43. The business has a fifty day moving average of $27.14 and a 200 day moving average of $25.89.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm’s revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.63 earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.